Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Plethora Solutions gets £4mm through debt placement

Executive Summary

Plethora Solutions (urological disorders) has raised £4mm ($8.1mm) through the placement of debt to ETV Capital. The 39-month notes will begin to be repaid early next year; they convert into shares, with the market price capped at £1.88. (The stock is currently averaging £1.48.) Plethora will use the proceeds to finish clinical trials and file for US approval of Invicorp, an erectile dysfunction therapeutic in-licensed from Senetek in early 2006.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Medical Devices
    • Diagnostic Equipment & Supplies
Deal Status
  • Final
Deal Type
  • Financing
    • Convertible Debt
    • Private Placement

Related Companies